Multiple myeloma treated with single agent dexamethasone

Authors

  • Sandhya Chapagain Acharya Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu
  • Ambuj Karn Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu
  • Bibek Acharya Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu
  • Bishnu D. Paudel Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu

DOI:

https://doi.org/10.3126/jkmc.v4i1.15026

Keywords:

Chemotherapy, Dexamethason, Multiple Myeloma

Abstract

Multiple myeloma is less frequently diagnosed in our part of the world. As per the hospital based cancer registry of Nepal, it accounts for 0.4% of all cancer cases diagnosed annually1. Usually they present with symptoms of chronic renal failure which is part of CRAB: elevated calcium (C), renal failure (R), anemia (A) and bone lesions (B). The symptoms and signs vary greatly as many organs can be affected by myeloma. Furthermore, the incidence is high in older age group with co morbidities demanding the patient tailored treatment. Here, we present a case of multiple myeloma which was treated with single agent dexamethasone. On initial evaluation patient had stage III disease with features of cord compression, so was started with immediate radiation therapy to the cervical and lumbar vertebrae followed by single agent dexamethasone as he denied further cytotoxic treatment. The patient is on regular follow up and in remission after six years of treatment. We are in the era where there is armor of chemotherapeutic agents along with bone marrow transplantation for the treatment of multiple myeloma. This case may represent an example and single agent dexamethasone can be an option for the treatment of the patient who is in poor general condition to receive the cytotoxic chemotherapy or denies to such therapy but it should be a choice only to a selected subgroup of patient population.

Journal of Kathmandu Medical College, Vol. 4(1) 2015, 26-28

Downloads

Download data is not yet available.
Abstract
768
PDF
636

Author Biographies

Sandhya Chapagain Acharya, Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu

Assistant Professor

Ambuj Karn, Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu

Assistant Professor

Bibek Acharya, Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu

Associate Professor

Bishnu D. Paudel, Department of Clinical Oncology, National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu

Professor

Downloads

Published

2016-05-31

How to Cite

Acharya, S. C., Karn, A., Acharya, B., & Paudel, B. D. (2016). Multiple myeloma treated with single agent dexamethasone. Journal of Kathmandu Medical College, 4(1), 26–28. https://doi.org/10.3126/jkmc.v4i1.15026

Issue

Vol. 4 No. 1 (2015)

Section

Original Research Articles

License

Copyright © Journal of Kathmandu Medical College
The ideas and opinions expressed by authors or articles summarized, quoted, or published in full text in this journal represent only the opinions of the authors and do not necessarily reflect the official policy of Journal of Kathmandu Medical College or the institute with which the author(s) is/are affiliated, unless so specified.

Authors convey all copyright ownership, including any and all rights incidental thereto, exclusively to JKMC, in the event that such work is published by JKMC. JKMC shall own the work, including 1) copyright; 2) the right to grant permission to republish the article in whole or in part, with or without fee; 3) the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and 4) the right to republish the work in a collection of articles in any other mechanical or electronic format.